Dr. Ramona Behshad, MD

Dr. Behshad practices at Slucare Rheumatology - Slucare Rheum Dpma - HOPD in Saint Louis, Missouri.

Dr. Behshad's NPI, 1124223011, was assigned on June 19, 2007. Dr. Behshad graduated from Cleveland Medical College, Homeopathic in 2007. Dr. Behshad holds Missouri license 2011007277.

Dr. Behshad's primary practice is Slucare Rheumatology - Slucare Rheum Dpma - HOPD, at 2315 Dougherty Ferry Rd, Saint Louis, MO 63122.

Dr. Behshad's primary practice is Slucare Rheumatology - Slucare Rheum Dpma - HOPD in Saint Louis, Missouri. Dr. Behshad is also affiliated with SSM Health Saint Louis University Hospital. The medical group on file is SLUCare Physician Group. Dmand AI also links Dr. Behshad to 1 more group practice or clinic, named with a free account. Dr. Behshad's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Behshad practices, 3 sites in all. Vendor and product names are available with a free account.

Mohs-micrographic surgery is Dr. Behshad's primary specialty in the NPI Registry, under taxonomy code 207ND0101X. Dr. Behshad is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Behshad's licenses on file in 3 states: Missouri, Illinois and Ohio.

CMS data shows 2,094 Medicare services from Dr. Behshad across 25 procedure codes in 2024, for 600 Medicare patients. Medicare paid $614,177 for them.

CMS counts 600 Medicare patients who saw Dr. Behshad in 2024. The largest group is 75 to 84, with 253 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 5% are also on Medicaid. Their average risk score is 1.18, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Behshad's median patient age at 74, with 47% women.

In 2024, Dr. Behshad wrote 337 Medicare Part D claims for 260 patients. 99% of them were for generic drugs. CMS names the drug for 283 of them, across 4 drugs with 11 or more claims each, at $1,711 in total drug cost. In 2023, CMS named 278 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Behshad for performance year 2024, reported as part of a group. Dr. Behshad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 129 procedures of melanoma (skin cancer) excision by Dr. Behshad, more than 95% of the clinicians it reports for that procedure.

Removal of nail tissue: 1 to 10 procedures (CMS shows small counts as a range)

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 34 papers to Dr. Behshad, published from 2011 to 2025. 2023 was the busiest year, with 5. The most frequent topics are Mohs Surgery, Skin Neoplasms and Carcinoma, Basal Cell. Dr. Behshad has published most often in Dermatol Surg. Dr. Behshad's most frequent co-authors are Ian A. Maher, MD, Addison Michael Demer, MD and Erica H. Lee, MD.

Dmand AI links Dr. Behshad to 1 clinical trial. Conditions studied include Cicatrix and Fibrosis.

CMS Open Payments shows 43 general payments to Dr. Behshad from 15 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 76% of the total. Medline Industries, Inc. paid the most, $900.

Dmand AI lists 2 awards for Dr. Behshad, most recently ASDS Fellow in 2011.

Dr. Behshad graduated from Cleveland Medical College, Homeopathic in 2007. Dr. Behshad is a member of AAD, ACP and ASDS.

Dr. Behshad is in network with 19 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.